Preclinical development

Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress

Retrieved on: 
Thursday, August 18, 2022
U.S. Securities and Exchange Commission, ESMO, Compte rendu, Risk, Drug discovery, GLOBE, 2021 Essex County Council election, Preclinical development, Private Securities Litigation Reform Act, Clinical trial, Congress, Security (finance), Annual report, Cancer, Patient, European Society for Medical Oncology, Therapy, COVID-19, Family, Twitter, CCA, Publication, News, FGFR, Safety, FGFR2, Webcast, Protein, Nasdaq, Pharmaceutical industry

Relay Therapeutics will host a conference call on September 12, 2022 at 8:00 am E.T.

Key Points: 
  • Relay Therapeutics will host a conference call on September 12, 2022 at 8:00 am E.T.
  • The ESMO website indicates that late breaking abstracts will be published on the September 7, 2022 at 7:05 pm E.T.
  • Relay Therapeutics will host a conference call and live webcast on September 12, 2022 at 8:00 am E.T.
  • The presentation from the ESMO Congress will also be available on the Relay Therapeutics website under Publications: https://relaytx.com/publications/ .

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 4, 2022
Epithelial cell adhesion molecule, GLOBE, AbbVie, Cancer, Investment, Clinical trial, Research, Patient, Bi-specific T-cell engager, Tumor microenvironment, Nivolumab, ...Continued, TCB, Risk, NIVO, Ipilimumab, SAN, Partnership, Safety, Webcast, Nasdaq, ID, Interferon, ESMO, ADC, IFN, Preclinical development, Therapeutic index, American Association for Cancer Research, Neoplasm, Therapy, COVID-19, Program, Amgen, AACR, Triple-negative breast cancer, Bristol Myers Squibb, United, Ministry of Education (Malaysia), CD71, CD166, IND, Twitter, EGFR, CD3, LinkedIn, Progression-free survival, Conjugation, Pharmaceutical industry, Video game, Vaccine, Fine chemical, Cryptocurrency

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported second quarter 2022 financial results and provided a business update.

Key Points: 
  • A data update for the fully enrolled squamous non-small cell lung cancer cohort is expected in the fourth quarter of 2022.
  • CytomX has prioritized the development of CX-2051 and an IND submission is planned in the second half of 2023.
  • General and administrative expenses increased by $2.4 million during the second quarter of 2022 to $11.7 million.
  • ET (2:00 p.m. PT) to discuss the financial results and provide a business update.

Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 4, 2022
Cell, Private Securities Litigation Reform Act, Annual report, Partnership, MMA, Gout, Degenerative disease, IND, Achievement, Immune tolerance, Immunoglobulin A, Intellectual property, Investor, DMD, Anticipation, Poster, II, Development, Safety, Autoimmunity, Disease, Pandemic, LGMD, Intention, GLOBE, Income, Preclinical development, PBC, Antibody, Primary, AAV, Completeness, Glycogen storage disease, Patient, Review, U.S. Securities and Exchange Commission, Primary biliary cholangitis, Autoimmune disease, Administration, Telephone, Clinical trial, Mouse, Nanoparticle, Company, Duchenne muscular dystrophy, Â, Society, Biotechnology, CSO, Research, Muscular dystrophy, NASDAQ, Immunoglobulin G, Pharmaceutical industry, Dentistry, Vaccine, Health insurance, Life insurance, Gene, Swedish Orphan Biovitrum, IgA nephropathy, Selecta

Building on this momentum, we enter the second half of 2022 with a focused portfolio of proprietary programs and an expected financial runway into mid-2024.

Key Points: 
  • Building on this momentum, we enter the second half of 2022 with a focused portfolio of proprietary programs and an expected financial runway into mid-2024.
  • Selecta is working with its partner, Cyrus Biotechnology, to develop a next generation IL-2 molecule to combine with ImmTOR and anticipates selecting an IL-2 candidate by year end 2022.
  • Selecta completed enrollment for DISSOLVE II in June 2022, with 153 study participants, triggering a $10 million milestone payment obligation from Sobi which has been received in Q3 2022.
  • Selecta management will host a conference call at 8:30 AM ET today to provide a corporate update and review the companys second quarter 2022 financial results.

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

Retrieved on: 
Thursday, August 4, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Annual report, COVID-19, Plasma kallikrein, Patient, NASDAQ, Pharmacy, Company, Review, Hope, Safety, Facebook, HAE, FDA, LinkedIn, Allergy, Time, Pharmacokinetics, Forward-looking statement, Drug discovery, Instagram, Preclinical development, Twitter, Therapy, Hereditary angioedema, Risk, Clinical trial, SEC, Half-life, Pharmaceutical industry, Asteria

STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for hereditary angioedema (HAE), with dosing once every three months or longer.

Key Points: 
  • STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for hereditary angioedema (HAE), with dosing once every three months or longer.
  • The Phase 1a trial is intended to establish clinical proof of concept for the differentiated profile anticipated for STAR-0215.
  • The Phase 1a randomized, double-blind, placebo-controlled single ascending dose trial is evaluating the safety, pharmacokinetics, and pharmacodynamics of STAR-0215 at a single U.S. center.
  • Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema.

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

Retrieved on: 
Monday, June 27, 2022
FDA, Annual report, CDK, Patient, Protein, Breast cancer, Preclinical development, Therapy, GLOBE, COVID-19, Program, Company, U.S. Securities and Exchange Commission, Interim, CCA, CDK2, Hyperphosphatemia, Toxicity, Compte rendu, Risk, Food, Cancer, FGFR2, Investment, BID, Security (finance), Clinical trial, Private Securities Litigation Reform Act, Drug discovery, Nasdaq, FGFR, News, Diarrhea, Family, Webcast, Safety, Twitter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mutation, NDA, QD, Pharmaceutical industry

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will announce today the anticipated registrational path for RLY-4008 and three new programs within a growing HR+/HER2- breast cancer franchise at a virtual analyst and investor event from 8:00 a.m. to 9:00 a.m. ET.

Key Points: 
  • We are excited to be announcing the anticipated registrational path for RLY-4008 and the maturation of the data to support that pathway.
  • In addition, building on the foundation of our PI3K franchise, we will outline a broad commitment to developing comprehensive treatment options for breast cancer patients.
  • Relay Therapeutics conducted an end-of-phase 1 meeting with the FDA to discuss next steps for the clinical development of RLY-4008.
  • The virtual analyst and investor event will be webcast live and may be accessed through Relay Therapeutics website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations .

ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology

Retrieved on: 
Tuesday, June 7, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Cardiology, Leadership, Johns Hopkins University, RNA, IND, Therapy, Amylin Pharmaceuticals, Peripheral nervous system, Fellow, Preclinical development, Pharmacology, NDA, Diplomate of National Board, American Board of Commissioners for Foreign Missions, Army Medical Department (United States), Oligonucleotide, UCB, Management, Pharmaceutical industry, Toxicology

ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team and development capabilities through the appointment of Andrew Seacat, Ph.D., Executive Director and Head of Toxicology.

Key Points: 
  • ADARx Pharmaceuticals, Inc. , a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team and development capabilities through the appointment of Andrew Seacat, Ph.D., Executive Director and Head of Toxicology.
  • Prior positions include Vice President, Preclinical Development at Latitude Pharmaceuticals and Senior Director, Preclinical Development at La Jolla Pharmaceuticals.
  • He also had increasing roles of responsibility in toxicology and drug safety at Allergan Pharmaceuticals, Amylin Pharmaceuticals, and 3M Medical Department.
  • ADARx Pharmaceuticals, Inc. , located in San Diego, is a biotechnology company committed to turning cutting-edge science into life-saving therapeutics.

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

Retrieved on: 
Tuesday, April 12, 2022
Atrasentan, Calcium, Kidney, Clinical trial, Pharmacokinetics, Kidney failure, COVID-19, Adult, Time, NASDAQ, Chronic kidney disease, Human, RNA, Primary hyperoxaluria, GLOBE, Calcium oxalate, Program, Patient, Preclinical development, PH2, Dialysis, LDHA, IgA nephropathy, SEC, Conditional sentence, Forward-looking statement, Safety, Immunoglobulin A, PH1, Disorder, Industry, Hematuria, Urinary tract infection, Liver, Therapy, Pharmaceutical industry, Chinook

CHK-336 exemplifies Chinooks commitment to discovering and developing novel precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers.

Key Points: 
  • CHK-336 exemplifies Chinooks commitment to discovering and developing novel precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers.
  • The phase 1, single-center, randomized, placebo-controlled double-blind single and multiple ascending dose clinical trial is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CHK-336 in up to 104 healthy volunteers.
  • BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy.
  • CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial.

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Retrieved on: 
Thursday, March 31, 2022
Private Securities Litigation Reform Act, Risk, GSK, Forward-looking statement, Tumor microenvironment, Program, Novartis, Cancer, U.S. Securities and Exchange Commission, CD73, Surface, GlaxoSmithKline, Preclinical development, IL-27, Immunoglobulin G, COVID-19, GLOBE, CD39, NK, Annual report, CCR8, Patient, CD112, Security (finance), Vaccine, Pharmaceutical industry, PVRIG

GSK4381562 is a fully human IgG1 antibody targeting PVRIG, an inhibitory protein expressed on natural killer cells (NK cells) and T cells.

Key Points: 
  • GSK4381562 is a fully human IgG1 antibody targeting PVRIG, an inhibitory protein expressed on natural killer cells (NK cells) and T cells.
  • As a result of this Phase 1 initiation, Surface will receive a $30 million milestone payment and is eligible to receive an additional $700 million in potential future milestone payments, as well as tiered royalties on global net sales.
  • In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1).
  • In addition, any forward-looking statements contained in this press release are based on assumptions that Surface Oncology believes to be reasonable as of this date.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, February 28, 2022
PLOS Neglected Tropical Diseases, HIV disease progression rates, Fever Dream, Conference call, RNA, Niran, COVID-19, Company, Sofosbuvir, Dengue fever, Severe acute respiratory syndrome coronavirus 2, Atea, RZR, Viremia, Nasdaq, Nature Communications, Survival, Research, Development, NS5A, Dengue virus, Viral load, Income tax, Safety, SOF, Founder, Patient, Yellow, Clinical trial, RNA polymerase II, Program, Cash, Doctor of Philosophy, HCV, PLOS, Administration, Lists of academic journals, Vital signs, Preclinical development, Alpha, BID, Protease, State Administrative Expenses, GLOBE, Income, IV, Adult, Antimicrobial Agents and Chemotherapy, Conference, PK, Infection, Time, Pharmaceutical industry, Medical device, Vaccine, Pharmacokinetics, Merck, Pharmacodynamics

BOSTON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.   

Key Points: 
  • ET today
    BOSTON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
  • Importantly, we have the financial strength and a seasoned management team to advance these programs through key clinical and regulatory inflection points, concluded Dr. Sommadossi.
  • Bemnifosbuvir Development Summary: In 2021, Atea reported data from two monotherapy Phase 2 clinical trials evaluating bemnifosbuvir for the treatment of COVID-19.
  • In addition, the Company recorded a $25.0 million expense during the fourth quarter 2021 due to an upfront payment related to the in-license of ruzasvir from Merck.

Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis

Retrieved on: 
Monday, February 28, 2022
Compliance, Psoriasis Area and Severity Index, Oral medicine, Failure, COVID-19, KOL, Scalp, Private Securities Litigation Reform Act, Research, Incidence, PGA, Depression, Risk, Growth, Inflammation, Atopic dermatitis, Safety, Disease, Skin, Fatigue, Capsule, Doctor of Philosophy, Population, Immune system, FAAD, Psoriasis, Journal of Transportation Engineering, Part B: Pavements, Confidentiality, Patient, Arthritis, GLOBE, Production part approval process, Ownership, Investor, Perelman School of Medicine at the University of Pennsylvania, Association, University, Associate, Adult, Metabolic syndrome, Preclinical development, FDA, T helper cell, Marketing, MD, Dermatology Life Quality Index, SEC, Pharmaceutical industry, Dermatology, Part

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data from the post-treatment follow-up (Part B) of its Phase 2 trial of EDP1815 in mild and moderate psoriasis which included durable and deeper clinical responses. EDP1815 is an investigational oral biologic currently in development for the treatment of a broad range of inflammatory diseases, including clinical programs in psoriasis, atopic dermatitis, and COVID-19.

Key Points: 
  • EDP1815 is an investigational oral biologic currently in development for the treatment of a broad range of inflammatory diseases, including clinical programs in psoriasis, atopic dermatitis, and COVID-19.
  • With the clinical responses and safety and tolerability results comparable to placebo observed in trials involving over 450 patients to-date, we look forward to advancing EDP1815 towards Phase 3 clinical trials.
  • These durable results were achieved without any new psoriasis medication being used during this time.
  • These data, combined with the durability data, suggest that longer dosing could lead to further deepening of the responses in some patients.